Depletion of CD25 + CD4 + T cells (Tregs) enhances the HBV-specific CD8 + T cell response primed by DNA immunization
Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8(+) T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25(+)C...
Saved in:
Published in | World journal of gastroenterology : WJG Vol. 11; no. 24; pp. 3772 - 3777 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
United States
Fourth Department of Internal Medicine (Gastroenterology and Hepatology), Tokyo Medical University, Tokyo, Japan%Department of Molecular and Preventive Medicine, Graduate School of Medicine, University of Tokyo,Tokyo, Japan%Department of Immunotherapeutics (Medinet), Graduate School of Medicine, University of Tokyo,Tokyo, Japan
28.06.2005
Baishideng Publishing Group Inc |
Subjects | |
Online Access | Get full text |
ISSN | 1007-9327 2219-2840 2219-2840 |
DOI | 10.3748/wjg.v11.i24.3772 |
Cover
Abstract | Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8(+) T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25(+)CD4(+) regulatory T (Treg) cells might be involved in a inhibition of CD8(+) T cell priming or in the modulation of the magnitude of the 'peak' antiviral CD8(+) T cell response primed by DNA immunization.
B10.D2 mice were immunized once with plasmid pCMV-S. Mice received 500 microg of anti-CD25 mAb injected intraperitoneally 3 d before DNA immunization to deplete CD25(+) cells. Induction of HBV-specific CD8(+) T cells in peripheral blood mononuclear cells (PBMCs) was measured by S28-39 peptide loaded DimerX staining and their function was analyzed by intracellular IFN-gamma staining.
DNA immunization induced HBV-specific CD8(+) T cells. At the peak T cell response (d 10), 7.1+/-2.0% of CD8(+) T cells were HBV-specific after DNA immunization, whereas 12.7+/-3.2% of CD8(+) T cells were HBV-specific in Treg-depleted mice, suggesting that DNA immunization induced more antigen-specific CD8(+) T cells in the absence of CD25(+) Treg cells (n = 6, P<0.05). Similarly, fewer HBV-specific memory T cells were detected in the presence of these cells (1.3+/-0.4%) in comparison to Treg-depleted mice (2.6+/-0.9%) on d 30 after DNA immunization (n = 6, P<0.01). Both IFN-gamma production and the avidity of the HBV-specific CD8(+) T cell response to antigen were higher in HBV-specific CD8(+) T cells induced in the absence of Treg cells.
CD25(+) Treg cells suppress priming and/or expansion of antigen-specific CD8(+) T cells during DNA immunization and the peak CD8(+) T cell response is enhanced by depleting this cell population. Furthermore, Treg cells appear to be involved in the contraction phase of the CD8(+) T cell response and may affect the quality of memory T cell pools. The elimination of Treg cells or their inhibition may be important in immunotherapeutic strategies to control HBV infection by inducing virus-specific cytotoxic T lymphocyte responses in chronically infected subjects. |
---|---|
AbstractList | Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8(+) T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25(+)CD4(+) regulatory T (Treg) cells might be involved in a inhibition of CD8(+) T cell priming or in the modulation of the magnitude of the 'peak' antiviral CD8(+) T cell response primed by DNA immunization.
B10.D2 mice were immunized once with plasmid pCMV-S. Mice received 500 microg of anti-CD25 mAb injected intraperitoneally 3 d before DNA immunization to deplete CD25(+) cells. Induction of HBV-specific CD8(+) T cells in peripheral blood mononuclear cells (PBMCs) was measured by S28-39 peptide loaded DimerX staining and their function was analyzed by intracellular IFN-gamma staining.
DNA immunization induced HBV-specific CD8(+) T cells. At the peak T cell response (d 10), 7.1+/-2.0% of CD8(+) T cells were HBV-specific after DNA immunization, whereas 12.7+/-3.2% of CD8(+) T cells were HBV-specific in Treg-depleted mice, suggesting that DNA immunization induced more antigen-specific CD8(+) T cells in the absence of CD25(+) Treg cells (n = 6, P<0.05). Similarly, fewer HBV-specific memory T cells were detected in the presence of these cells (1.3+/-0.4%) in comparison to Treg-depleted mice (2.6+/-0.9%) on d 30 after DNA immunization (n = 6, P<0.01). Both IFN-gamma production and the avidity of the HBV-specific CD8(+) T cell response to antigen were higher in HBV-specific CD8(+) T cells induced in the absence of Treg cells.
CD25(+) Treg cells suppress priming and/or expansion of antigen-specific CD8(+) T cells during DNA immunization and the peak CD8(+) T cell response is enhanced by depleting this cell population. Furthermore, Treg cells appear to be involved in the contraction phase of the CD8(+) T cell response and may affect the quality of memory T cell pools. The elimination of Treg cells or their inhibition may be important in immunotherapeutic strategies to control HBV infection by inducing virus-specific cytotoxic T lymphocyte responses in chronically infected subjects. AIM: Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8+ T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25+CD4+ regulatory T (Treg) cells might be involved in a inhibition of CD8+ T cell priming or in the modulation of the magnitude of the ‘peak’ antiviral CD8+ T cell response primed by DNA immunization. METHODS: B10.D2 mice were immunized once with plasmid pCMV-S. Mice received 500 μg of anti-CD25 mAb injected intraperitoneally 3 d before DNA immunization to deplete CD25+ cells. Induction of HBV-specific CD8+ T cells in peripheral blood mononuclear cells (PBMCs) was measured by S28-39 peptide loaded DimerX staining and their function was analyzed by intracellular IFN-γ staining. RESULTS: DNA immunization induced HBV-specific CD8+ T cells. At the peak T cell response (d 10), 7.1±2.0% of CD8+ T cells were HBV-specific after DNA immunization, whereas 12.7±3.2% of CD8+ T cells were HBV-specific in Treg-depleted mice, suggesting that DNA immunization induced more antigen-specific CD8+ T cells in the absence of CD25+ Treg cells (n = 6, P<0.05). Similarly, fewer HBV-specific memory T cells were detected in the presence of these cells (1.3±0.4%) in comparison to Treg-depleted mice (2.6±0.9%) on d 30 after DNA immunization (n = 6, P<0.01). Both IFN-γ production and the avidity of the HBV-specific CD8+ T cell response to antigen were higher in HBV-specific CD8+ T cells induced in the absence of Treg cells. CONCLUSION: CD25+ Treg cells suppress priming and/or expansion of antigen-specific CD8+ T cells during DNA immunization and the peak CD8+ T cell response is enhanced by depleting this cell population. Furthermore, Treg cells appear to be involved in the contraction phase of the CD8+ T cell response and may affect the quality of memory T cell pools. The elimination of Treg cells or their inhibition may be important in immunotherapeutic strategies to control HBV infection by inducing virus-specific cytotoxic T lymphocyte responses in chronically infected subjects. R5; AIM: Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8+ T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25+CD4+ regulatory T (Treg) cells might be involved in a inhibition of CD8+T cell priming or in the modulation of the magnitude of the'peak' antiviral CD8+ T cell response primed by DNA immunization. METHODS: B10.D2 mice were immunized once with plasmid pCMV-S. Mice received 500 μg of anti-CD25 mAb injected intraperitoneally 3 d before DNA immunization to deplete CD25+ cells. Induction of HBV-specific CD8+ T ceils in peripheral blood mononuclear cells (PBMCs) was measured by S28-39 peptide loaded DimerX staining and their function was analyzed by intracellular IFN-γ staining.RESULTS: DNA immunization induced HBV-specific CD8+ T cells. At the peak T cell response (d 10), 7.1±2.0% of CD8+ T cells were HBV-specific after DNA immunization, whereas 12.7±3.2% of CD8+ T cells were HBV-specific in Treg-depleted mice, suggesting that DNA immunization induced more antigen-specific CD8+ T cells in the absence of CD25+ Treg cells (n = 6, P<0.05). Similarly, fewer HBVspecific memory T cells were detected in the presence of these cells (1.3±0.4%) in comparison to Treg-depleted mice (2.6±0.9%) on d 30 after DNA immunization (n = 6, P<0.01). Both IFN-γ production and the avidity of the HBV-specific CD8+ T cell response to antigen were higher in HBV-specific CD8+ T cells induced in the absence of Treg cells.CONCLUSION: CD25+ Treg cells suppress priming and/or expansion of antigen-specific CD8+ T cells during DNA immunization and the peak CD8+ T cell response is enhanced by depleting this cell population. Furthermore, Treg cells appear to be involved in the contraction phase of the CD8+ T ceil response and may affect the quality of memory T cell pools. The elimination of Treg cells or their inhibition may be important in immunotherapeutic strategies to control HBV infection by inducing virus-specific cytotoxic T lymphocyte responses in chronically infected subjects. Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8(+) T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25(+)CD4(+) regulatory T (Treg) cells might be involved in a inhibition of CD8(+) T cell priming or in the modulation of the magnitude of the 'peak' antiviral CD8(+) T cell response primed by DNA immunization.AIMPersistent hepatitis B virus (HBV) infection is characterized by a weak CD8(+) T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and boost these suboptimal responses may facilitate viral clearance in chronically infected individuals. Therefore, we examined whether CD25(+)CD4(+) regulatory T (Treg) cells might be involved in a inhibition of CD8(+) T cell priming or in the modulation of the magnitude of the 'peak' antiviral CD8(+) T cell response primed by DNA immunization.B10.D2 mice were immunized once with plasmid pCMV-S. Mice received 500 microg of anti-CD25 mAb injected intraperitoneally 3 d before DNA immunization to deplete CD25(+) cells. Induction of HBV-specific CD8(+) T cells in peripheral blood mononuclear cells (PBMCs) was measured by S28-39 peptide loaded DimerX staining and their function was analyzed by intracellular IFN-gamma staining.METHODSB10.D2 mice were immunized once with plasmid pCMV-S. Mice received 500 microg of anti-CD25 mAb injected intraperitoneally 3 d before DNA immunization to deplete CD25(+) cells. Induction of HBV-specific CD8(+) T cells in peripheral blood mononuclear cells (PBMCs) was measured by S28-39 peptide loaded DimerX staining and their function was analyzed by intracellular IFN-gamma staining.DNA immunization induced HBV-specific CD8(+) T cells. At the peak T cell response (d 10), 7.1+/-2.0% of CD8(+) T cells were HBV-specific after DNA immunization, whereas 12.7+/-3.2% of CD8(+) T cells were HBV-specific in Treg-depleted mice, suggesting that DNA immunization induced more antigen-specific CD8(+) T cells in the absence of CD25(+) Treg cells (n = 6, P<0.05). Similarly, fewer HBV-specific memory T cells were detected in the presence of these cells (1.3+/-0.4%) in comparison to Treg-depleted mice (2.6+/-0.9%) on d 30 after DNA immunization (n = 6, P<0.01). Both IFN-gamma production and the avidity of the HBV-specific CD8(+) T cell response to antigen were higher in HBV-specific CD8(+) T cells induced in the absence of Treg cells.RESULTSDNA immunization induced HBV-specific CD8(+) T cells. At the peak T cell response (d 10), 7.1+/-2.0% of CD8(+) T cells were HBV-specific after DNA immunization, whereas 12.7+/-3.2% of CD8(+) T cells were HBV-specific in Treg-depleted mice, suggesting that DNA immunization induced more antigen-specific CD8(+) T cells in the absence of CD25(+) Treg cells (n = 6, P<0.05). Similarly, fewer HBV-specific memory T cells were detected in the presence of these cells (1.3+/-0.4%) in comparison to Treg-depleted mice (2.6+/-0.9%) on d 30 after DNA immunization (n = 6, P<0.01). Both IFN-gamma production and the avidity of the HBV-specific CD8(+) T cell response to antigen were higher in HBV-specific CD8(+) T cells induced in the absence of Treg cells.CD25(+) Treg cells suppress priming and/or expansion of antigen-specific CD8(+) T cells during DNA immunization and the peak CD8(+) T cell response is enhanced by depleting this cell population. Furthermore, Treg cells appear to be involved in the contraction phase of the CD8(+) T cell response and may affect the quality of memory T cell pools. The elimination of Treg cells or their inhibition may be important in immunotherapeutic strategies to control HBV infection by inducing virus-specific cytotoxic T lymphocyte responses in chronically infected subjects.CONCLUSIONCD25(+) Treg cells suppress priming and/or expansion of antigen-specific CD8(+) T cells during DNA immunization and the peak CD8(+) T cell response is enhanced by depleting this cell population. Furthermore, Treg cells appear to be involved in the contraction phase of the CD8(+) T cell response and may affect the quality of memory T cell pools. The elimination of Treg cells or their inhibition may be important in immunotherapeutic strategies to control HBV infection by inducing virus-specific cytotoxic T lymphocyte responses in chronically infected subjects. |
Author | Furuichi, Yoshihiro |
AuthorAffiliation | Fourth Department of Internal Medicine (Gastroenterology and Hepatology), Tokyo Medical University, Tokyo, Japan%Department of Molecular and Preventive Medicine, Graduate School of Medicine, University of Tokyo,Tokyo, Japan%Department of Immunotherapeutics (Medinet), Graduate School of Medicine, University of Tokyo,Tokyo, Japan |
AuthorAffiliation_xml | – name: Fourth Department of Internal Medicine (Gastroenterology and Hepatology), Tokyo Medical University, Tokyo, Japan%Department of Molecular and Preventive Medicine, Graduate School of Medicine, University of Tokyo,Tokyo, Japan%Department of Immunotherapeutics (Medinet), Graduate School of Medicine, University of Tokyo,Tokyo, Japan |
Author_xml | – sequence: 1 givenname: Yoshihiro surname: Furuichi fullname: Furuichi, Yoshihiro |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/15968737$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkc2P0zAQxS20iO0u3DkhHxACoRR_JY4vSEsLLNIKLoWr5TiT1lVqZ-Nkq_LX49CKBQ5wsSXPm5n3fr5AZz54QOgpJXMuRflmv13P7yidOybSg2QP0IwxqjJWCnKGZpQQmSnO5Dm6iHFLCOM8Z4_QOc1VUUouZ2hYQtfC4ILHocGLJcvx63SJdK6whbaN-OWqh3V8hcFvjLcQ8bABfP3uWxY7sK5xNunLX3rcQ-yCj4C73u2gxtUBLz9fYbfbjd59N9Oqx-hhY9oIT073Jfr64f1qcZ3dfPn4aXF1k1me8yEz0jaNMrSsi6aiVqiCKpNbkYoVr6kEqXJQthZ1DjxXQjJFZEkrXlaqKnnJLxE9zh19Zw5707Z6MmX6g6ZETwR1IqgTQZ0I6olg6nl77OnGKtm34Ife3PcF4_SfFe82eh3utOC0IJynAc-PA_bGN8av9TaMvU8xp12MkJwJwkSSvTjt6cPtCHHQOxcngMZDGKMuUriCcpqEz343dJ_g9IdJUBwFtg8x9tBo64afnJM_1_4rKvmr8b90fgArGb-D |
CitedBy_id | crossref_primary_10_1128_JVI_00036_09 crossref_primary_10_2217_imt_09_26 crossref_primary_10_3389_fimmu_2022_993246 crossref_primary_10_1016_j_bbrc_2008_04_191 crossref_primary_10_1016_j_imlet_2015_05_018 crossref_primary_10_1016_j_clim_2010_12_012 crossref_primary_10_1146_annurev_immunol_021908_132723 crossref_primary_10_1097_CJI_0000000000000120 crossref_primary_10_1089_vim_2008_0046 crossref_primary_10_1128_JVI_02111_12 crossref_primary_10_1002_hep_22684 crossref_primary_10_1002_hep_25765 crossref_primary_10_1089_vim_2016_0052 crossref_primary_10_1002_eji_200737888 crossref_primary_10_1089_aid_2012_0320 crossref_primary_10_1007_s11596_012_0093_8 crossref_primary_10_1111_j_1600_0838_2010_01288_x crossref_primary_10_1111_imm_12006 crossref_primary_10_3390_vaccines12090992 crossref_primary_10_1016_j_jhep_2010_04_020 crossref_primary_10_1089_aid_2011_0353 crossref_primary_10_1111_sji_12018 crossref_primary_10_4049_jimmunol_1101649 crossref_primary_10_1016_j_cellimm_2013_02_004 crossref_primary_10_1128_IAI_01500_06 crossref_primary_10_3892_ijo_2014_2402 crossref_primary_10_1038_nri2189 crossref_primary_10_1016_j_vaccine_2008_03_026 crossref_primary_10_1371_journal_pone_0104627 crossref_primary_10_1016_j_ejphar_2013_01_064 crossref_primary_10_1038_nri3041 crossref_primary_10_1371_journal_pone_0040359 crossref_primary_10_1016_j_ijbiomac_2014_01_017 crossref_primary_10_3389_fcimb_2017_00247 crossref_primary_10_1007_s12250_014_3396_z crossref_primary_10_1111_j_1751_7915_2011_00283_x crossref_primary_10_4161_hv_28517 crossref_primary_10_1016_j_vaccine_2008_11_042 crossref_primary_10_1371_journal_pone_0151717 crossref_primary_10_1016_j_intimp_2021_107761 |
Cites_doi | 10.4049/jimmunol.165.12.6833 10.4049/jimmunol.160.3.1212 10.1016/S0092-8674(00)80856-9 10.1016/S0952-7915(96)80034-3 10.4049/jimmunol.170.1.394 10.1038/87730 10.1146/annurev.immunol.18.1.927 10.4049/jimmunol.172.7.4123 10.1146/annurev.immunol.15.1.617 10.1084/jem.181.3.1047 10.1038/87720 10.4049/jimmunol.155.3.1151 10.1128/JVI.67.4.2376-2380.1993 10.4049/jimmunol.173.4.2211 10.1172/JCI200423395 10.1002/1521-4141(200205)32:5<1282::AID-IMMU1282>3.0.CO;2-# 10.1073/pnas.132254399 10.1146/annurev.iy.13.040195.000333 10.1084/jem.20011347 10.1038/nature01152 10.1084/jem.20030171 10.1016/S0002-9440(10)64980-2 10.4049/jimmunol.150.10.4659 10.1128/JVI.76.17.8609-8620.2002 10.1038/nri778 10.1089/hum.1995.6.11-1447 |
ClassificationCodes | R5 |
ContentType | Journal Article |
Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. 2005 Baishideng Publishing Group Inc. All rights reserved. 2005 |
Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. – notice: 2005 Baishideng Publishing Group Inc. All rights reserved. 2005 |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 2B. 4A8 92I 93N PSX TCJ 5PM ADTOC UNPAY |
DOI | 10.3748/wjg.v11.i24.3772 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
DeliveryMethod | fulltext_linktorsrc |
EISSN | 2219-2840 |
EndPage | 3777 |
ExternalDocumentID | 10.3748/wjg.v11.i24.3772 PMC4316033 wjg200524024 15968737 10_3748_wjg_v11_i24_3772 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Grant-in-Aid for Scientific Research |
GroupedDBID | --- 123 29R 2WC 36B 53G 5VR 8WL 92F 92I AAKDD AAYXX ACGFO AENEX AFUIB ALMA_UNASSIGNED_HOLDINGS CCEZO CHBEP CIEJG CITATION CS3 CW9 DIK DU5 E3Z EBS EJD F5P FRP GX1 HYE OK1 P2P RNS RPM TCJ TGQ TR2 WFFXF XSB 2B. 93N CGR CUY CVF ECM EIF FA0 M~E NPM 7X8 4A8 PSX 5PM ADTOC UNPAY |
ID | FETCH-LOGICAL-c353t-a7cff9a18d6fb1c49619a5c4353b3d17e795e9cd4d5e35947290781b38b9b8383 |
IEDL.DBID | UNPAY |
ISSN | 1007-9327 2219-2840 |
IngestDate | Tue Aug 19 23:49:19 EDT 2025 Tue Sep 30 16:53:46 EDT 2025 Thu May 29 04:01:26 EDT 2025 Fri Jul 11 05:42:02 EDT 2025 Wed Oct 16 00:47:23 EDT 2024 Thu Apr 24 23:12:54 EDT 2025 Wed Oct 01 02:36:21 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 24 |
Keywords | Regulatory T cell (Treg) Vaccine Hepatitis B virus DNA immunization Cytotoxic T lymphocyte |
Language | English |
License | cc-by-nc |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c353t-a7cff9a18d6fb1c49619a5c4353b3d17e795e9cd4d5e35947290781b38b9b8383 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Correspondence to: Kazuhiro Kakimi, MD, PhD, Department of Immunotherapeutics (Medinet), Graduate School of Medicine, The University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-8655, Japan. kakimi@m.u-tokyo.ac.jp Author contributions: All authors contributed equally to the work. Telephone: +81-3-3815-5411 Fax: +81-3-5684-3989 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://www.wjgnet.com/1007-9327/full/v11/i24/3772.htm |
PMID | 15968737 |
PQID | 67956131 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | unpaywall_primary_10_3748_wjg_v11_i24_3772 pubmedcentral_primary_oai_pubmedcentral_nih_gov_4316033 wanfang_journals_wjg200524024 proquest_miscellaneous_67956131 pubmed_primary_15968737 crossref_citationtrail_10_3748_wjg_v11_i24_3772 crossref_primary_10_3748_wjg_v11_i24_3772 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2005-06-28 |
PublicationDateYYYYMMDD | 2005-06-28 |
PublicationDate_xml | – month: 06 year: 2005 text: 2005-06-28 day: 28 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | World journal of gastroenterology : WJG |
PublicationTitleAlternate | World J Gastroenterol |
PublicationTitle_FL | WORLD JOURNAL OF GASTROENTEROLOGY |
PublicationYear | 2005 |
Publisher | Fourth Department of Internal Medicine (Gastroenterology and Hepatology), Tokyo Medical University, Tokyo, Japan%Department of Molecular and Preventive Medicine, Graduate School of Medicine, University of Tokyo,Tokyo, Japan%Department of Immunotherapeutics (Medinet), Graduate School of Medicine, University of Tokyo,Tokyo, Japan Baishideng Publishing Group Inc |
Publisher_xml | – name: Fourth Department of Internal Medicine (Gastroenterology and Hepatology), Tokyo Medical University, Tokyo, Japan%Department of Molecular and Preventive Medicine, Graduate School of Medicine, University of Tokyo,Tokyo, Japan%Department of Immunotherapeutics (Medinet), Graduate School of Medicine, University of Tokyo,Tokyo, Japan – name: Baishideng Publishing Group Inc |
References | ref13 ref12 ref15 ref14 ref11 ref10 ref2 ref1 ref17 ref16 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref27 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
References_xml | – ident: ref13 doi: 10.4049/jimmunol.165.12.6833 – ident: ref23 doi: 10.4049/jimmunol.160.3.1212 – ident: ref24 doi: 10.1016/S0092-8674(00)80856-9 – ident: ref2 doi: 10.1016/S0952-7915(96)80034-3 – ident: ref19 doi: 10.4049/jimmunol.170.1.394 – ident: ref11 doi: 10.1038/87730 – ident: ref8 doi: 10.1146/annurev.immunol.18.1.927 – ident: ref27 doi: 10.4049/jimmunol.172.7.4123 – ident: ref7 doi: 10.1146/annurev.immunol.15.1.617 – ident: ref4 doi: 10.1084/jem.181.3.1047 – ident: ref12 doi: 10.1038/87720 – ident: ref22 doi: 10.4049/jimmunol.155.3.1151 – ident: ref5 doi: 10.1128/JVI.67.4.2376-2380.1993 – ident: ref26 doi: 10.4049/jimmunol.173.4.2211 – ident: ref25 doi: 10.1172/JCI200423395 – ident: ref17 doi: 10.1002/1521-4141(200205)32:5<1282::AID-IMMU1282>3.0.CO;2-# – ident: ref15 doi: 10.1073/pnas.132254399 – ident: ref21 – ident: ref1 doi: 10.1146/annurev.iy.13.040195.000333 – ident: ref14 doi: 10.1084/jem.20011347 – ident: ref18 doi: 10.1038/nature01152 – ident: ref16 doi: 10.1084/jem.20030171 – ident: ref3 doi: 10.1016/S0002-9440(10)64980-2 – ident: ref6 doi: 10.4049/jimmunol.150.10.4659 – ident: ref9 doi: 10.1128/JVI.76.17.8609-8620.2002 – ident: ref10 doi: 10.1038/nri778 – ident: ref20 doi: 10.1089/hum.1995.6.11-1447 |
SSID | ssj0023352 |
Score | 1.9879061 |
Snippet | Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8(+) T cell response to HBV. Immunotherapeutic strategies that overcome tolerance and... R5; AIM: Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8+ T cell response to HBV. Immunotherapeutic strategies that overcome... AIM: Persistent hepatitis B virus (HBV) infection is characterized by a weak CD8+ T cell response to HBV. Immunotherapeutic strategies that overcome tolerance... |
SourceID | unpaywall pubmedcentral wanfang proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 3772 |
SubjectTerms | Animals Brief Reports CD4-Positive T-Lymphocytes - cytology CD4-Positive T-Lymphocytes - metabolism CD4-Positive T-Lymphocytes - virology CD8-Positive T-Lymphocytes - cytology CD8-Positive T-Lymphocytes - virology DNA, Viral - immunology Hepatitis B Vaccines - pharmacology Hepatitis B virus - immunology Hepatitis B, Chronic - immunology Hepatitis B, Chronic - therapy Immunization Male Mice Mice, Inbred Strains Receptors, Interleukin-2 - metabolism |
Title | Depletion of CD25 + CD4 + T cells (Tregs) enhances the HBV-specific CD8 + T cell response primed by DNA immunization |
URI | https://www.ncbi.nlm.nih.gov/pubmed/15968737 https://www.proquest.com/docview/67956131 https://d.wanfangdata.com.cn/periodical/wjg200524024 https://pubmed.ncbi.nlm.nih.gov/PMC4316033 https://www.wjgnet.com/1007-9327/full/v11/i24/3772.htm |
UnpaywallVersion | publishedVersion |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2219-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023352 issn: 1007-9327 databaseCode: DIK dateStart: 19980101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 2219-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023352 issn: 1007-9327 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2219-2840 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0023352 issn: 1007-9327 databaseCode: RPM dateStart: 19970101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwELaW7gEuPMQrwC4-cGBZ5VXbcXwsLasKiYpDC8spshOnWyhu1bSsll_PTJIWykqIPcceOfaM_Y1n5jMhryKRx7AHGp9LGfm8jDBIqKUfpRLGLTByg8XJH0bJcMLfn4vzA5Jsa2EwrfLy6xTc8nqbxhi-DxBDhngbHf6I43DW5SEDTAi-5fdb5DDBwFKHHE5GH3tf6tBm2wNflQNz9GH_jZr4JDKthCA8ADEBiAlQzP55dA1kXs-VvL1xS311qefzus7HldpN_ziSzu6Rz9ufaTJRvgWbtQnyn3_xPN78b--Tuy1Kpb1GrR6QA-seEjewS6TqXji6KGl_0BWn_QE_HVO8_K_o6_HKTqsTat0FalJFAVrS4dtPPhZzYkISdEnb1nTVpOZausTnBQpqruhg1KOzulqlqQx9RCZn78b9od8-1-DnTLC1r2VelkrHaZGUJs65At9MixzwGDOsiKWVSliVF7wQlgnFAdYj05BhqVEmBU_5Mem4hbNPCdVKiEIYnZSM8SLKFYDALpcps0rhLbZHwu2iZXnLZY5Paswz8GlwmTOYVfD_4wzmL8P588jJrsey4fH4R9uXWz3IwNhwWrSzi02VJRLrgFnskSeNVvyWJVSSSiY9Ivf0ZdcAabz3v7jZRU3njWQEEWMeebPTrP8Y4lGrelm751TYpqbR4gC7nt1E2HNypyakjRIwlheks15t7BFArbU5rm-_jlvr-gUsECNM |
linkProvider | Unpaywall |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwELaW7gEuPMRjAyz4wIFllVdtx_GxtKwqJCoOLSynyE6cbqG4VdOyWn49M0laKCsh9hx75Ngz9jeemc-EvIpEHsMeaHwuZeTzMsIgoZZ-lEoYt8DIDRYnfxglwwl_fy7OD0iyrYXBtMrLr1Nwy-ttGmP4PkAMGeJtdPgjjsNZl4cMMCH4lt9vkcMEA0sdcjgZfex9qUObbQ98VQ7M0Yf9N2rik8i0EoLwAMQEICZAMfvn0TWQeT1X8vbGLfXVpZ7P6zofV2o3_eNIOrtHPm9_pslE-RZs1ibIf_7F83jzv71P7rYolfYatXpADqx7SNzALpGqe-HooqT9QVec9gf8dEzx8r-ir8crO61OqHUXqEkVBWhJh28_-VjMiQlJ0CVtW9NVk5pr6RKfFyiouaKDUY_O6mqVpjL0EZmcvRv3h377XIOfM8HWvpZ5WSodp0VSmjjnCnwzLXLAY8ywIpZWKmFVXvBCWCYUB1iPTEOGpUaZFDzlx6TjFs4eEaqVEIUwOikZ40WUKwCBXS5TZpXCW2yPhNtFy_KWyxyf1Jhn4NPgMmcwq-D_xxnMX4bz55GTXY9lw-Pxj7Yvt3qQgbHhtGhnF5sqSyTWAbPYI08arfgtS6gklUx6RO7py64B0njvf3Gzi5rOG8kIIsY88manWf8xxONW9bJ2z6mwTU2jxQF2Pb2JsGfkTk1IGyVgLM9JZ73a2GOAWmvzorWrX12WIjw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Depletion+of+CD25%2BCD4%2BT+cells+%28Tregs%29+enhances+the+HBV-specific+CD8%2B+T+cell+response+primed+by+DNA+immunization&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Furuichi%2C+Yoshihiro&rft.au=Tokuyama%2C+Hirotake&rft.au=Ueha%2C+Satoshi&rft.au=Kurachi%2C+Makoto&rft.date=2005-06-28&rft.issn=1007-9327&rft.volume=11&rft.issue=24&rft.spage=3772&rft_id=info:doi/10.3748%2Fwjg.v11.i24.3772&rft.externalDBID=NO_FULL_TEXT |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fwjg%2Fwjg.jpg |